Comparative Pharmacology
Head-to-head clinical analysis: ESTRADIOL VALERATE AND DIENOGEST versus LYGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRADIOL VALERATE AND DIENOGEST versus LYGEN.
ESTRADIOL VALERATE AND DIENOGEST vs LYGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol valerate is a prodrug of estradiol, an estrogen that binds to estrogen receptors (ERα and ERβ) to regulate gene transcription, promoting endometrial growth and suppressing gonadotropins. Dienogest is a progestin with partial antiandrogenic activity, binding to progesterone receptors to inhibit endometrial proliferation and ovulation, and reducing androgen synthesis.
Lysergic acid diethylamide (LSD) acts as a partial agonist at serotonin 5-HT2A receptors in the brain, leading to altered glutamatergic signaling and neural network modulation.
One tablet (2 mg estradiol valerate and 3 mg dienogest) once daily orally, without interruption, following the first day of menstrual cycle.
For adults, administer 500 mg orally twice daily with or without food.
None Documented
None Documented
Estradiol valerate: Terminal half-life of estradiol is 13-15 hours; valerate ester is rapidly hydrolyzed, so systemic estradiol half-life applies. Dienogest: Terminal half-life ~8-10 hours, increasing to ~12-14 hours with multiple dosing due to competitive inhibition of CYP3A4.
12 hours; prolonged to 24 hours in severe renal impairment (CrCl <30 mL/min)
Estradiol valerate: Renal (primarily as glucuronide and sulfate conjugates) ~40%, Fecal ~60%. Dienogest: Renal ~60% (mostly unchanged), Fecal ~30%.
Renal (90% as unchanged drug), biliary/fecal (10%)
Category D/X
Category C
Estrogen
Estrogen